Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from BeiGene Ltd ( (HK:6160) ).
BeOne Medicines has granted 53,322 restricted share units (RSUs), equivalent to 693,186 underlying shares or about 0.04% of its issued share capital, to 155 grantees under its 2016 Share Option and Incentive Plan. The awards, which include a small allocation to an external scientific adviser, are structured to vest mainly in 25% annual tranches over four years (with certain specific vesting schedules and potential acceleration on termination or change of control), underscoring the company’s use of equity incentives to retain talent and align employees’ and advisers’ interests with long-term shareholder value while causing only minimal share dilution.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$194.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
BeOne Medicines Ltd. is a Switzerland-incorporated biopharmaceutical company listed in Hong Kong, focused on developing medicines in its principal therapeutic areas, supported by scientific advisory services to maintain and enhance its competitiveness in the sector.
Average Trading Volume: 3,952,422
Technical Sentiment Signal: Buy
Current Market Cap: HK$316.1B
See more insights into 6160 stock on TipRanks’ Stock Analysis page.